Loading
companiesCompany
Ipsen
Ipsen is the French pharma behind Onivyde (liposomal irinotecan) and the NALIRIFOX regimen, and marketer of tovorafenib in Europe.
Overview
Ipsen is the Paris-based pharmaceutical company, listed as IPN.PA, behind Onivyde, the liposomal irinotecan at the heart of the NALIRIFOX regimen for pancreatic cancer, and the European marketer of tovorafenib for paediatric low-grade glioma under rights from Day One. Its oncology portfolio also includes Cabometyx outside the United States, tazemetostat for epithelioid sarcoma and somatostatin analogues for neuroendocrine tumours, with NAPOLI 3 establishing NALIRIFOX and CLARINET supporting lanreotide. OnCo links it to pancreatic ductal adenocarcinoma, glioma, neuroendocrine tumours and epithelioid sarcoma, and to the cabozantinib, irinotecan, tazemetostat and tovorafenib records. Whether NALIRIFOX becomes the default first-line regimen on value as well as efficacy is the open question. Each product has its own page.
Headquarters
Paris, FR
Scorecard
All companies#22of 1244 companies, score 98
- approved products +42
- targets +14
- modalities +4
- regions +6
- 24-month regulatory events +8
- registry trials +30
- failures -6
7 approved, 0 in phase 3, 0 earlier, 7 targets, 2,299 registry studies. Formula on the scorecards page.
Type
Large pharma · IPN.PA
Stage
Public
Website
ApprovedCytotoxic regimen
NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen
NALIRIFOX is a version of FOLFIRINOX using a liposome-wrapped irinotecan, approved in 2024 as a first-line option for metastatic pancreatic cancer.
ApprovedSmall-molecule type II RAF inhibitor
Tovorafenib · Ojemda
Tovorafenib is a pill for the most common childhood brain tumour, low-grade glioma driven by BRAF changes, approved in 2024.
ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)
Cabozantinib · Cabometyx
A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.
ApprovedTopoisomerase I inhibitor (camptothecin prodrug)
Irinotecan (and liposomal irinotecan) · Camptosar / Onivyde
Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads.
ApprovedLiposome-encapsulated topoisomerase I inhibitor (cytotoxic)
Liposomal irinotecan · Onivyde
Irinotecan wrapped in a fat bubble so it circulates longer. It is approved for pancreatic cancer, and in bile duct and gallbladder cancer one Korean trial found it helped as second-line treatment while a German trial did not.
ApprovedPeptide hormone analogue (SSTR2 agonist)
Somatostatin analogues (octreotide, lanreotide) · Sandostatin LAR, Somatuline Depot
Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours.
Withdrawnsmall molecule
An oral drug aimed at the tissue around the tumour rather than the cancer cells. It held the cancer back on scans and, if anything, shortened life.
WithdrawnSmall-molecule EZH2 inhibitor
Tazemetostat · Tazverik
Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.
ApprovedGnRH agonist depot
Triptorelin · Trelstar
Triptorelin (Trelstar) is a one-, three- or six-monthly injection that switches off testosterone production for men with advanced prostate cancer.
Similar pages
- TrialRASolute 302
Shares NAPOLI-1, NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Liposomal irinotecan, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
- TermPancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)
Shares NAPOLI-1, NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV), Liposomal irinotecan, Metastatic pancreatic ductal adenocarcinoma.
- CancerLung neuroendocrine tumours (typical and atypical carcinoid)
Shares SPINET, CLARINET, Somatostatin analogues (octreotide, lanreotide), Cabozantinib.
- Key paperConroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)
Shares Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial, Irinotecan (and liposomal irinotecan), Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Metastatic pancreatic ductal adenocarcinoma.
- CompanyActive Biotech
Shares Tasquinimod, 10TASQ10.
- Key paperMetastatic Pancreatic Cancer: ASCO Guideline Update
Shares Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial, Liposomal irinotecan, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma.
- PersonDaniel D. Von Hoff
Shares Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
- Key paperTazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Shares Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in), Epithelioid sarcoma.
cancers
drugs
ApprovedSmall-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)
Cabozantinib · Cabometyx
ApprovedTopoisomerase I inhibitor (camptothecin prodrug)
Irinotecan (and liposomal irinotecan) · Camptosar / Onivyde
ApprovedLiposome-encapsulated topoisomerase I inhibitor (cytotoxic)
Liposomal irinotecan · Onivyde
ApprovedCytotoxic regimen
NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) · Onivyde regimen
ApprovedPeptide hormone analogue (SSTR2 agonist)
Somatostatin analogues (octreotide, lanreotide) · Sandostatin LAR, Somatuline Depot
Withdrawnsmall molecule
WithdrawnSmall-molecule EZH2 inhibitor
Tazemetostat · Tazverik
ApprovedSmall-molecule type II RAF inhibitor
Tovorafenib · Ojemda
ApprovedGnRH agonist depot
Triptorelin · Trelstar
companies
trials
10TASQ10A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid TumoursA Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid TumoursA Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor TherapiesCLARINETEffect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate CancerFirst-in-Human Study of ICT01 in Patients With Advanced CancerGETUG-AFU 17Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsLiposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal CancerNAPOLI 3NAPOLI-1SPINETTazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)